EVOTEC SE ADR 1/2 O.N. - Asset Resilience Ratio
EVOTEC SE ADR 1/2 O.N. (EVTA) has an Asset Resilience Ratio of 3.88% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read EVTA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2024)
This chart shows how EVOTEC SE ADR 1/2 O.N.'s Asset Resilience Ratio has changed over time. See net assets of EVOTEC SE ADR 1/2 O.N. for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down EVOTEC SE ADR 1/2 O.N.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see EVOTEC SE ADR 1/2 O.N. (EVTA) market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €68.76 Million | 3.88% |
| Total Liquid Assets | €68.76 Million | 3.88% |
Asset Resilience Insights
- Limited Liquidity: EVOTEC SE ADR 1/2 O.N. maintains only 3.88% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
EVOTEC SE ADR 1/2 O.N. Industry Peers by Asset Resilience Ratio
Compare EVOTEC SE ADR 1/2 O.N.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for EVOTEC SE ADR 1/2 O.N. (2021–2024)
The table below shows the annual Asset Resilience Ratio data for EVOTEC SE ADR 1/2 O.N..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 4.73% | €90.41 Million ≈ $105.70 Million |
€1.91 Billion ≈ $2.24 Billion |
+0.59pp |
| 2023-12-31 | 4.14% | €93.20 Million ≈ $108.96 Million |
€2.25 Billion ≈ $2.63 Billion |
-9.45pp |
| 2022-12-31 | 13.58% | €306.61 Million ≈ $358.46 Million |
€2.26 Billion ≈ $2.64 Billion |
+6.46pp |
| 2021-12-31 | 7.12% | €159.17 Million ≈ $186.09 Million |
€2.24 Billion ≈ $2.61 Billion |
-- |
About EVOTEC SE ADR 1/2 O.N.
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just " Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammati… Read more